CO6251254A2 - Uso de inhibidores de piridopirimidinona de pi3k en el tratamiento del cancer - Google Patents
Uso de inhibidores de piridopirimidinona de pi3k en el tratamiento del cancerInfo
- Publication number
- CO6251254A2 CO6251254A2 CO09126924A CO09126924A CO6251254A2 CO 6251254 A2 CO6251254 A2 CO 6251254A2 CO 09126924 A CO09126924 A CO 09126924A CO 09126924 A CO09126924 A CO 09126924A CO 6251254 A2 CO6251254 A2 CO 6251254A2
- Authority
- CO
- Colombia
- Prior art keywords
- optionally substituted
- alkyl
- heteroaryl
- optionally
- heterocycloalkyl
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 title 1
- 108091007960 PI3Ks Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 5
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 125000003545 alkoxy group Chemical group 0.000 abstract 3
- 125000003282 alkyl amino group Chemical group 0.000 abstract 3
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 3
- 125000001475 halogen functional group Chemical group 0.000 abstract 3
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 3
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 125000001188 haloalkyl group Chemical group 0.000 abstract 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000004103 aminoalkyl group Chemical group 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 125000004181 carboxyalkyl group Chemical group 0.000 abstract 1
- -1 cyano, amino Chemical group 0.000 abstract 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 1
- 238000001794 hormone therapy Methods 0.000 abstract 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
- 229910052740 iodine Inorganic materials 0.000 abstract 1
- 229940036571 iodine therapy Drugs 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 230000005855 radiation Effects 0.000 abstract 1
- 230000002285 radioactive effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92289907P | 2007-04-10 | 2007-04-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6251254A2 true CO6251254A2 (es) | 2011-02-21 |
Family
ID=39627802
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO09126924A CO6251254A2 (es) | 2007-04-10 | 2009-11-09 | Uso de inhibidores de piridopirimidinona de pi3k en el tratamiento del cancer |
Country Status (31)
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200726767A (en) * | 2005-07-04 | 2007-07-16 | Astrazeneca Ab | Chemical compounds 2 |
| DK1940839T3 (da) * | 2005-10-07 | 2013-10-14 | Exelixis Inc | Pyridopyrimidione Inhibitors of P13Ka |
| US7989622B2 (en) * | 2005-10-07 | 2011-08-02 | Exelixis, Inc. | Phosphatidylinositol 3-kinase inhibitors and methods of their use |
| CA2658725A1 (en) | 2006-08-16 | 2008-02-21 | Exelixis, Inc. | Using pi3k and mek modulators in treatments of cancer |
| US8188113B2 (en) * | 2006-09-14 | 2012-05-29 | Deciphera Pharmaceuticals, Inc. | Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| SA08280783B1 (ar) * | 2007-01-11 | 2011-04-24 | استرازينيكا ايه بي | مشتقات بيريدوبيريميدين كمثبطات pde4 |
| UA100979C2 (ru) | 2007-04-10 | 2013-02-25 | Экселиксис, Инк. | Применение пиридопиримидиноновых ингибиторов pi3k альфа для лечения рака |
| JP5726515B2 (ja) * | 2007-04-11 | 2015-06-03 | エクセリクシス， インク． | Ｐｉ３ｋ−アルファのキナゾリン阻害剤を用いた阻害による治療方法 |
| US8470834B2 (en) | 2008-08-20 | 2013-06-25 | Merck Sharp & Dohme Corp. | AZO-substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
| US8715638B2 (en) | 2008-08-20 | 2014-05-06 | Merck Sharp & Dohme Corp. | Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
| AU2009282567B2 (en) | 2008-08-20 | 2014-10-02 | Merck Sharp & Dohme Corp. | Substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
| WO2010022125A1 (en) | 2008-08-20 | 2010-02-25 | Schering Corporation | Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
| TW201139436A (en) | 2010-02-09 | 2011-11-16 | Exelixis Inc | Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K and mTOR in combination with autophagy inhibitors |
| WO2012027536A1 (en) * | 2010-08-26 | 2012-03-01 | Bristol-Myers Squibb Company | Combination of anti-ctla4 antibody with braf inhibitors for the synergistic treatment of proliferative diseases |
| EP2616442B8 (en) | 2010-09-14 | 2018-10-17 | Exelixis, Inc. | Inhibitors of pi3k-delta and methods of their use and manufacture |
| WO2012065019A2 (en) | 2010-11-12 | 2012-05-18 | Exelixis, Inc. | Pyridopyrimidinone inhibitors of p13k alpha |
| US9441013B2 (en) * | 2011-05-17 | 2016-09-13 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Melanocortin 1 receptor ligands and methods of use |
| TW201306842A (zh) * | 2011-06-15 | 2013-02-16 | Exelixis Inc | 使用ｐｉ３ｋ／ｍｔｏｒ吡啶並嘧啶酮抑制劑及苯達莫司汀及／或利妥昔單抗治療惡性血液疾病之組合療法 |
| WO2013015833A2 (en) * | 2011-07-28 | 2013-01-31 | Genentech, Inc | Pik3ca h1047r knock-in non-human animal breast cancer model |
| WO2013056067A1 (en) * | 2011-10-13 | 2013-04-18 | Exelixis, Inc. | Compounds for use in the treatment of basal cell carcinoma |
| BR112014010492A2 (pt) | 2011-11-01 | 2017-04-25 | Exelixis Inc | n-(3-{[(3-{[2-cloro-5-(metóxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-metilalaninamida como inibidor de fosfatidilinositol 3-cinase para o tratamento de malignidades linfoproliferativas |
| JP6126615B2 (ja) * | 2011-11-11 | 2017-05-10 | インテリカイン， エルエルシー | キナーゼ阻害剤の組み合わせおよびそれらの使用 |
| JP2015503568A (ja) | 2011-12-27 | 2015-02-02 | カドモン コーポレイション，リミティド ライアビリティ カンパニー | トラスツズマブに不応性の乳癌の治療方法 |
| US8461179B1 (en) | 2012-06-07 | 2013-06-11 | Deciphera Pharmaceuticals, Llc | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| EP2872161B1 (en) | 2012-06-26 | 2020-12-16 | Del Mar Pharmaceuticals | Dianhydrogalactitol for use in treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations |
| US8980259B2 (en) * | 2012-07-20 | 2015-03-17 | Novartis Ag | Combination therapy |
| HRP20190537T1 (hr) | 2012-08-07 | 2019-06-28 | Novartis Ag | Farmaceutske kombinacije koje sadrže inhibitor b-raf, inhibitor egfr i po izboru inhibitor pi3k-alfa |
| KR20160061911A (ko) | 2013-04-08 | 2016-06-01 | 데니스 엠. 브라운 | 최적하 투여된 화학 화합물의 치료 효과 |
| US9950194B2 (en) | 2014-09-09 | 2018-04-24 | Mevion Medical Systems, Inc. | Patient positioning system |
| US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
| KR102793563B1 (ko) | 2016-03-04 | 2025-04-11 | 다이호야쿠힌고교 가부시키가이샤 | 악성 종양 치료용 제제 및 조성물 |
| EP3497103B1 (en) * | 2016-08-15 | 2021-05-05 | Pfizer Inc. | Pyridopyrimdinone cdk2/4/6 inhibitors |
| JP7027699B2 (ja) * | 2017-05-09 | 2022-03-02 | 住友ゴム工業株式会社 | タイヤトレッドおよびタイヤ |
| BR112020015572A2 (pt) | 2018-01-31 | 2021-02-02 | Deciphera Pharmaceuticals, Llc | terapia de combinação para o tratamento da mastocitose |
| MX2020008016A (es) | 2018-01-31 | 2020-11-09 | Deciphera Pharmaceuticals Llc | Terapia de combinación para el tratamiento de tumores del estroma gastrointestinal. |
| FI3769765T3 (fi) | 2018-03-19 | 2024-05-15 | Taiho Pharmaceutical Co Ltd | Natriumalkyylisulfaattia sisältävä farmaseuttinen koostumus |
| BR112022002609A2 (pt) | 2019-08-12 | 2022-08-09 | Deciphera Pharmaceuticals Llc | Métodos de tratamento de tumores estromais gastrointestinais |
| WO2021030405A1 (en) | 2019-08-12 | 2021-02-18 | Deciphera Pharmaceuticals, Llc | Ripretinib for treating gastrointestinal stromal tumors |
| EP4073055A4 (en) * | 2019-12-10 | 2024-02-28 | The Trustees of Indiana University | INHIBITORS OF REPLICATION PROTEIN A (RPA)-DNA INTERACTION |
| CN118948773A (zh) | 2019-12-30 | 2024-11-15 | 德西费拉制药有限责任公司 | 1-(4溴-5-(1乙基-7-(甲氨基)-2侧氧基-1,2-二氢-1,6-萘啶-3基)-2氟苯基)-3-苯基脲的组合物 |
| RS65058B1 (sr) | 2019-12-30 | 2024-02-29 | Deciphera Pharmaceuticals Llc | Formulacije inhibitora amorfne kinaze i postupci njihove primene |
| KR102195221B1 (ko) | 2019-12-31 | 2020-12-24 | 서울대학교산학협력단 | 포스파티딜이노시톨 3-키나아제 억제제 및 프로그램화 세포 사멸 단백질 1 억제제를 포함하는, 삼중음성 유방암의 방사선 병용 치료용 약학적 조성물 |
| CN111358952B (zh) * | 2020-04-15 | 2022-03-15 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 一种抗肿瘤药物组合物及其制剂和应用 |
| EP4433061A4 (en) * | 2021-11-18 | 2025-09-03 | Onconova Therapeutics Inc | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER |
| US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7019002B2 (en) * | 2001-12-11 | 2006-03-28 | Pharmacia & Upjohn, S.P.A. | Pyridopyrimidinones derivatives as telomerase inhibitors |
| AU2003249212C1 (en) * | 2002-07-15 | 2011-10-27 | Symphony Evolution, Inc. | Receptor-type kinase modulators and methods of use |
| EP1718645A1 (en) * | 2004-02-18 | 2006-11-08 | Warner-Lambert Company LLC | 2-(pyridin-3-ylamino)-pyrido 2,3-d pyrimidin-7-ones |
| ES2292130T3 (es) * | 2004-05-04 | 2008-03-01 | Warner-Lambert Company Llc | Pirido(2,3-d)pirimidin-7-onas pirrolil-sustituidas y derivados de las mismas como agentes terapeuticos. |
| WO2007004698A1 (ja) * | 2005-07-06 | 2007-01-11 | Sbc Corporation | 漏洩電流検出装置及び漏洩電流検出方法 |
| DK1940839T3 (da) * | 2005-10-07 | 2013-10-14 | Exelixis Inc | Pyridopyrimidione Inhibitors of P13Ka |
| US8247408B2 (en) | 2005-10-07 | 2012-08-21 | Exelixis, Inc. | Pyridopyrimidinone inhibitors of PI3Kα for the treatment of cancer |
| US7989622B2 (en) * | 2005-10-07 | 2011-08-02 | Exelixis, Inc. | Phosphatidylinositol 3-kinase inhibitors and methods of their use |
| CA2658725A1 (en) | 2006-08-16 | 2008-02-21 | Exelixis, Inc. | Using pi3k and mek modulators in treatments of cancer |
| BRPI0716749B8 (pt) * | 2006-09-15 | 2021-05-25 | Pfizer Prod Inc | compostos pirido (2,3-d) pirimidinona, seu uso como inibidores pi3 e composição farmacêutica que os compreende |
| UA100979C2 (ru) | 2007-04-10 | 2013-02-25 | Экселиксис, Инк. | Применение пиридопиримидиноновых ингибиторов pi3k альфа для лечения рака |
| JP5726515B2 (ja) * | 2007-04-11 | 2015-06-03 | エクセリクシス， インク． | Ｐｉ３ｋ−アルファのキナゾリン阻害剤を用いた阻害による治療方法 |
| EA018964B1 (ru) | 2007-04-11 | 2013-12-30 | Экселиксис, Инк. | СОЕДИНЕНИЯ ПИРИДО[2,3-d]ПИРИМИДИН-7-ОНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3K-АЛЬФА ДЛЯ ЛЕЧЕНИЯ РАКА |
| CA2683784A1 (en) | 2007-04-11 | 2008-10-23 | Exelixis, Inc. | Pyrido[2,3-d]pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer |
| WO2010039740A1 (en) * | 2008-09-30 | 2010-04-08 | Exelixis, Inc. | PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα AND MTOR |
-
2008
- 2008-04-09 UA UAA200911419A patent/UA100979C2/ru unknown
- 2008-04-09 EP EP08742677.1A patent/EP2139484B9/en active Active
- 2008-04-09 DK DK08742677.1T patent/DK2139484T3/da active
- 2008-04-09 MY MYPI20094214 patent/MY150697A/en unknown
- 2008-04-09 CN CN200880018725A patent/CN101715345A/zh active Pending
- 2008-04-09 BR BRPI0810206-6A2A patent/BRPI0810206A2/pt not_active IP Right Cessation
- 2008-04-09 ES ES08742677T patent/ES2430614T3/es active Active
- 2008-04-09 CA CA2683641A patent/CA2683641C/en not_active Expired - Fee Related
- 2008-04-09 MX MX2009010930A patent/MX2009010930A/es active IP Right Grant
- 2008-04-09 CN CN201210032620.4A patent/CN102727498B/zh not_active Expired - Fee Related
- 2008-04-09 EA EA200970932A patent/EA020022B1/ru not_active IP Right Cessation
- 2008-04-09 PL PL08742677T patent/PL2139484T3/pl unknown
- 2008-04-09 NZ NZ580110A patent/NZ580110A/en not_active IP Right Cessation
- 2008-04-09 SI SI200831004T patent/SI2139484T1/sl unknown
- 2008-04-09 RS RS20130384A patent/RS52939B/en unknown
- 2008-04-09 US US12/595,219 patent/US8513266B2/en active Active
- 2008-04-09 HR HRP20130688AT patent/HRP20130688T1/hr unknown
- 2008-04-09 ME MEP-2009-303A patent/ME00936B/me unknown
- 2008-04-09 AU AU2008236562A patent/AU2008236562B2/en not_active Ceased
- 2008-04-09 JP JP2010503045A patent/JP2010523670A/ja active Pending
- 2008-04-09 KR KR1020097023351A patent/KR101626435B1/ko not_active Expired - Fee Related
- 2008-04-09 WO PCT/US2008/004573 patent/WO2008124161A1/en active Application Filing
- 2008-04-09 PT PT87426771T patent/PT2139484E/pt unknown
-
2009
- 2009-09-29 ZA ZA200906764A patent/ZA200906764B/xx unknown
- 2009-09-30 TN TNP2009000400A patent/TN2009000400A1/fr unknown
- 2009-10-01 IL IL201284A patent/IL201284A/en active IP Right Grant
- 2009-10-09 HN HN2009003002A patent/HN2009003002A/es unknown
- 2009-10-09 DO DO2009000243A patent/DOP2009000243A/es unknown
- 2009-11-02 MA MA32318A patent/MA31358B1/fr unknown
- 2009-11-09 CR CR11100A patent/CR11100A/es unknown
- 2009-11-09 EC EC2009009724A patent/ECSP099724A/es unknown
- 2009-11-09 CO CO09126924A patent/CO6251254A2/es not_active Application Discontinuation
-
2013
- 2013-09-19 JP JP2013194611A patent/JP2014034576A/ja active Pending
-
2014
- 2014-03-24 JP JP2014059561A patent/JP2014139217A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6251254A2 (es) | Uso de inhibidores de piridopirimidinona de pi3k en el tratamiento del cancer | |
| AR080151A1 (es) | Metodos para tratar cancer usando inhibidores de piridopirimidinona de pi 3k y mtor en combinacion con inhibidores de autofagia | |
| AR064608A1 (es) | Derivados de pirazolo-quinazolina sustituidos, composiciones farmaceuticas que los contienen. proceso para su preparacion y uso de los mismos como agentes anticancer. | |
| AR059957A1 (es) | DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER. | |
| DOP2018000187A (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo | |
| AU2018256624A1 (en) | JAK2 and ALK2 inhibitors and methods for their use | |
| AR053120A1 (es) | Aminopiridinas como inhibidores de beta secretasa | |
| AR086357A1 (es) | Derivados de indazol sustituidos activos como inhibidores de quinasas | |
| GEP20156389B (en) | Oxazolidin-2-one compounds and their usage as pi3ks inhibitors | |
| CO6390066A2 (es) | Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas | |
| JP2014034576A5 (enrdf_load_stackoverflow) | ||
| AR084935A1 (es) | Derivados de tipo azaindazol o diazaindazol como medicamentos | |
| TW200621762A (en) | Novel compounds | |
| PE20142339A1 (es) | Derivados macrociclicos para el tratamiento de enfermedades | |
| UY30559A1 (es) | Derivados de morfolino pirimidina, procesos de preparacion, composiciones conteniéndolos y aplicaciones | |
| AR040047A1 (es) | 1-(aminoalquil)-3-sulfonilazaindoles como ligandos de la 5-hidroxitriptamina-6 | |
| MX2015008975A (es) | Analogos de tiadiazol y metodos para el tratamiento de afecciones relacionadas con deficiencia del gen de supervivencia de las neuronas motoras (smn). | |
| CO6341631A2 (es) | Derivados de 1,2,4 - oxadiazol y su uso terapéutico | |
| AR085316A1 (es) | Derivados de pirrolo[2,3-b]piridina, utiles para la modulacion de quinasas | |
| NI201000002A (es) | Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o p13k. | |
| MX2011011335A (es) | Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamifero de rapamicina. | |
| NZ588994A (en) | Phenyl and benzodioxinyl substituted indazoles derivatives | |
| AR042042A1 (es) | Administracion combinada de una indolinona con un agente quimioterapeutico para trastornos de proliferacion celular | |
| PH12014501542B1 (en) | Substituted pyrrolidine -2- carboxamides | |
| AR089568A1 (es) | Compuestos heterociclicos y sus metodos de usos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |